Eficacia y seguridad del uso de prostaglandina E1, en pacientes con cardiopatía congénita ductus dependiente Hospital Dr. Francisco de Icaza Bustamante
No hay miniatura disponible
Fecha
2018
Autores
Título de la revista
ISSN de la revista
Título del volumen
Editor
Universidad de Guayaquil. Facultad de Ciencias Médicas. Escuela de Graduados
Resumen
Las cardiopatías congénitas ductus dependientes son un grupo de patologías en la que la meta primordial es impedir que el ductus arterioso se cierre hasta lograr la resolución quirúrgica de las mismas. El objetivo del trabajo es demostrar la eficacia y seguridad del uso de prostaglandina E1 en pacientes con cardiopatía congénita ductus dependiente. Es un estudio descriptivo, no experimental, retrospectivo, realizado en el Hospital Dr. Francisco de Icaza en los pacientes que ingresaron con diagnóstico de cardiopatía congénita ductus dependiente y que recibieron prostaglandina E1. El estudio estuvo conformado por 13 neonatos, predominó el sexo masculino con 53.8%. Las cardiopatías más frecuentes fueron la atresia pulmonar con septum integro con un 61.54% de presentación seguida de la transposición de grandes vasos con el 15.38%. El procedimiento quirúrgico que más se realizó fue fistula sistémico pulmonar con el 46.15% de los casos, hubo dos pacientes que fallecieron antes de una opción quirúrgica que es el 15.38%. La eficacia de la prostaglandina E1 se observó dentro de las 2 primeras horas luego de haber iniciado la infusión de prostaglandina E1. No se reportaron efectos adversos con el uso de prostaglandina E1. Las infecciones presentadas por los pacientes del estudio se mostraron antes del inicio de la medicación. La administración de prostaglandina E1 demostró ser segura y efectiva en el manejo de las cardiopatías congénitas ductus dependientes.
Ductus-dependent congenital heart diseases are a group of pathologies in which the primary goal is to prevent the ductus arteriosus from closing until surgical resolution of the same. The objective of the work is to demonstrate the efficacy and safety of the use of prostaglandin E1 in patients with congenital ductus dependent heart disease. This is a descriptive, non-experimental, retrospective study conducted at the Dr. Francisco de Icaza Hospital in patients admitted with a diagnosis of congenital ductus-dependent heart disease who received prostaglandin E1. The study consisted of 13 neonates, predominantly male with 53.8%. The most frequent heart diseases were pulmonary atresia with an integrated septum with a 61.54% presentation followed by the transposition of large vessels with 15.38%. The surgical procedure that was most performed was systemic pulmonary shunt with 46.15% of the cases, there were two patients who died before a surgical option that is 15.38%. The efficacy of prostaglandin E1 was observe within the first 2 hours after starting the infusion of prostaglandin E1. No adverse effects were report with prostaglandin E1 use. The infections presented by the study patients were show before the start of the medication. The administration of prostaglandin E1 proved to be safe and effective in the management of ductus-dependent congenital heart diseases.
Ductus-dependent congenital heart diseases are a group of pathologies in which the primary goal is to prevent the ductus arteriosus from closing until surgical resolution of the same. The objective of the work is to demonstrate the efficacy and safety of the use of prostaglandin E1 in patients with congenital ductus dependent heart disease. This is a descriptive, non-experimental, retrospective study conducted at the Dr. Francisco de Icaza Hospital in patients admitted with a diagnosis of congenital ductus-dependent heart disease who received prostaglandin E1. The study consisted of 13 neonates, predominantly male with 53.8%. The most frequent heart diseases were pulmonary atresia with an integrated septum with a 61.54% presentation followed by the transposition of large vessels with 15.38%. The surgical procedure that was most performed was systemic pulmonary shunt with 46.15% of the cases, there were two patients who died before a surgical option that is 15.38%. The efficacy of prostaglandin E1 was observe within the first 2 hours after starting the infusion of prostaglandin E1. No adverse effects were report with prostaglandin E1 use. The infections presented by the study patients were show before the start of the medication. The administration of prostaglandin E1 proved to be safe and effective in the management of ductus-dependent congenital heart diseases.
Descripción
Palabras clave
Cardiopatías congénitas, Alprostadil, Conducto arterioso permeable, Estudios retrospectivos, Epidemiología descriptiva, Cantón Guayaquil, Hospital del Niño Francisco de Icaza Bustamante, Ecuador